Welcome to the POTP board, the DPP-IV company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: drbio45 who wrote (49)	11/19/2006 6:53:25 PM
From: rareearth42	Read Replies (2) of 90

drbio45, I beg to differ regarding your interpretation of MCU's trial on a couple of points. first of all, most vitamins on the market contain pyridoxal-5-phosphate, precisely the chemical composition of MCU's "MC-1". Take a look at this article for a clear description: theheart.org Other vitamins may have a mixture of pyridoxine, pyridoxamine, and pyridoxal phosphate, but pyridoxal-5-phosphate is the active form of the vitamin. Next, the MEND-CABG trial did indeed show a significant benefit of the 250 mg dose of vitamin B6, but the 750 mg dose wasn't significant. This is a big red flag, as I would expect a real effect to have a dose response. Remember we were all excited about ALXN's significant results in their comparable big phase 2 studies with pexelizumab. The bottom line is that I don't see what will stop generic competition and I'm not particularly confident the phase 3 trial will be successful, so MCU is not for me. RE42

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next